piracetam has been researched along with Absence Status in 135 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs." | 9.27 | Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus. ( Amedeo, S; Bertone, I; Cagnotti, G; D'Angelo, A; Dappiano, E; Gardini, G; Guerriero, G; Lentini, L; Odore, R, 2018) |
| "IV Levetiracetam controls status epilepticus or cluster seizures with an efficacy comparable to that of phenytoin." | 9.24 | Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. ( Al-Amrani, K; Al-Asmi, A; Al-Hashim, A; Ganguly, SS; Gujjar, AR; Jacob, PC; Nandhagopal, R, 2017) |
| "The purpose of this study was to compare safety and efficacy of intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) in management of status epilepticus (SE)." | 9.20 | Levetiracetam versus phenytoin in management of status epilepticus. ( Bhalla, A; Chakravarthi, S; Goyal, MK; Modi, M; Singh, P, 2015) |
| "Levetiracetam is effective in individuals with electrical status epilepticus during sleep with tolerable side effects." | 9.19 | Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience. ( Cai, FC; Chen, X; Chen, XQ; Gao, L; Huang, SP; Pang, BD; Yang, ZX; Zhang, WN; Zhao, M; Zou, LP, 2014) |
| "We performed a double-blind placebo-controlled crossover study of the effects of spike activity during sleep and when awake on learning, long-term memory, vigilance and behavior before and after treatment with levetiracetam in children with electrical status epilepticus during sleep." | 9.17 | Subclinical epileptiform activity in children with electrical status epilepticus during sleep: effects on cognition and behavior before and after treatment with levetiracetam. ( Bakke, KA; Bjørnæs, H; Brager-Larsen, LM; Eriksson, AS; Heminghyt, E; Larsson, PG; Rytter, E, 2013) |
| "For the management of status epilepticus (SE), lorazepam (LOR) is recommended as the first and phenytoin or fosphenytoin as the second choice." | 9.16 | Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. ( Kalita, J; Maurya, PK; Misra, UK, 2012) |
| "To evaluate the feasibility and safety of intravenous (iv) levetiracetam (LEV) added to the standard therapeutic regimen in adults with status epilepticus (SE), and as secondary objective to assess a population pharmacokinetic (PK) model for ivLEV in patients with SE." | 9.14 | Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ( Engelsman, J; Peeters, E; Touw, DJ; Uges, JW; van Huizen, MD; Vecht, CJ; Wilms, EB, 2009) |
| "The objective of the study was to perform a systematic review and meta-analysis to evaluate the efficacy and safety of levetiracetam (LEV) or phenytoin (PHT) as second-line treatment for status epilepticus (SE)." | 9.05 | Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. ( DeMott, JM; Gottlieb, M; Peksa, GD; Slocum, GW, 2020) |
| "Over last fifty years, intravenous (iv) phenytoin (PHT) loading dose has been the treatment of choice for patients with benzodiazepine-resistant convulsive status epilepticus and several guidelines recommended this treatment regimen with simultaneous iv diazepam." | 8.98 | Why we prefer levetiracetam over phenytoin for treatment of status epilepticus. ( Amantini, A; Campostrini, R; Giannasi, G; Giorgi, FS; Giovannelli, F; Nazerian, P; Paganini, M; Zaccara, G, 2018) |
| "The aim of this study was to conduct a meta-analysis of published studies to directly compare intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) or IV valproate (VPA) as second-line treatment of status epilepticus (SE), to indirectly compare intravenous IV LEV with IV VPA using common reference-based indirect comparison meta-analysis, and to verify whether results of indirect comparisons are consistent with results of head-to-head randomized controlled trials (RCTs) directly comparing IV LEV with IV VPA." | 8.93 | Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. ( Bragazzi, N; Brigo, F; Nardone, R; Trinka, E, 2016) |
| "Recommended loading doses of levetiracetam (LEV) for status epilepticus (SE) treatment have increased over time." | 8.31 | Status epilepticus prognosis following levetiracetam administration: Analysis of loading doses. ( Kuffer, I; Novy, J; Rossetti, AO, 2023) |
| "We aimed to evaluate the blood concentration of levetiracetam (LEV), as a second-line drug, in patients with status epilepticus (SE) in an emergency clinical setting." | 8.02 | Blood concentration of levetiracetam after bolus administration in patients with status epilepticus. ( Hotta, M; Kaneko, J; Kondo, M; Kubota, M; Kuno, M; Nagano, M; Sugaya, K; Tagami, T; Takase, H; Unemoto, K, 2021) |
| "Because of the lack of studies comparing the efficacy and safety of levetiracetam and valproate before the induction of general anesthesia in the treatment of convulsive refractory status epilepticus in children, we aimed to compare the effectiveness of these antiepileptic drugs in patients with convulsive status epilepticus admitted to the Pediatric Intensive Care Unit between 2011 and 2014." | 7.83 | A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children. ( Ağın, H; Ceylan, G; Güzel, O; İşgüder, R; Yılmaz, Ü, 2016) |
| "Our previous study showed that treatment with levetiracetam (LEV) after status epilepticus (SE) termination by diazepam might prevent the development of spontaneous recurrent seizures via the inhibition of neurotoxicity induced by brain edema events." | 7.83 | Levetiracetam treatment influences blood-brain barrier failure associated with angiogenesis and inflammatory responses in the acute phase of epileptogenesis in post-status epilepticus mice. ( Chiba, Y; Dohgu, S; Ishihara, Y; Itoh, K; Kataoka, Y; Komori, R; Nochi, H; Takata-Tsuji, F; Taniguchi, R; Ueno, M, 2016) |
| "To clarify the effect of levetiracetam (LEV) for acute and chronic seizure control in acute encephalitis with refractory, repetitive partial seizures (AERRPS)." | 7.81 | Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase. ( Imamura, A; Maegaki, Y; Maruta, K; Matsunami, K; Narita, A; Nishimura, Y; Ohno, K; Saiki, Y; Saito, Y; Sokota, T; Sugihara, S; Tamasaki, A; Ueda, R, 2015) |
| "To investigate the antiepileptic and protective effects of intravenous levetiracetam (iv LEV) in the rhesus monkey model of acute status epilepticus (SE)." | 7.81 | Pretreatment with intravenous levetiracetam in the rhesus monkey Coriaria lactone-induced status epilepticus model. ( Chen, F; Chen, SH; Cheng, L; Hong, Z; Lei, S; Li, HX; Li, JM; Li, L; Yang, TH; Zhou, D, 2015) |
| "Epilepsy with electrical status epilepticus in sleep (ESES) is a devastating disease, and we sought to evaluate the efficacy of levetiracetam (LEV) for the treatment of patients with this epileptic encephalopathy in China." | 7.81 | Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep. ( Cai, F; Chen, J; Feng, C; Hu, Y; Jiang, L, 2015) |
| "Intravenous levetiracetam is an option for treatment of status epilepticus (SE) and acute repetitive seizures (ARS)." | 7.81 | Intravenous levetiracetam in Thai children and adolescents with status epilepticus and acute repetitive seizures. ( Khongkhatithum, C; Thampratankul, L; Visudtibhan, A; Wiwattanadittakul, N, 2015) |
| "To assess the efficacy of intravenous (IV) levetiracetam (LEV) in the treatment of status epilepticus (SE) and treatment outcomes." | 7.81 | Intravenous levetiracetam treatment in status epilepticus: A prospective study. ( Atmaca, MM; Bebek, N; Gurses, C; Orhan, EK, 2015) |
| "To compare intravenous phenytoin (PHT) and intravenous lacosamide (LCM) for treatment of status epilepticus after failure of the first and second drug." | 7.80 | Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. ( Berning, S; Kellinghaus, C; Stögbauer, F, 2014) |
| "Intravenous levetiracetam (LEV) has been shown to be effective and safe in treating adults with refractory status epilepticus (SE)." | 7.80 | Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus. ( Chae, JH; Choi, J; Hwang, H; Hwang, YS; Kim, H; Kim, JS; Kim, KJ; Lee, JH; Lim, BC; Ryu, HW, 2014) |
| "To study the efficacy of levetiracetam (LEV) combined with short-term clonazepam (CZP) in the treatment of electrical status epilepticus during sleep (ESES) in children with benign childhood epilepsy with centrotemporal spikes (BECCT)." | 7.80 | [Efficacy of levetiracetam combined with short-term clonazepam in treatment of electrical status epilepticus during sleep in children with benign childhood epilepsy with centrotemporal spikes]. ( Chen, L; Su, TF; Xu, SQ, 2014) |
| "Levetiracetam has been reported to be well tolerated and effective in status epilepticus (SE) refractory to benzodiazepine." | 7.79 | The effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampus. ( Choi, HC; Kang, TC; Kim, JE; Kim, YI; Lee, DS; Ryu, HJ; Song, HK, 2013) |
| " Approximately 30-40% of brain tumors patients who present with status epilepticus (SE) will not respond to typical therapy consisting of benzodiazepines and phenytoin (PHT), resulting in patients with refractory status epilepticus (RSE)." | 7.78 | Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. ( Doreswamy, M; Gingrich, KJ; Kolls, BJ; Swisher, CB; Vredenburgh, JJ, 2012) |
| "We present the first reported case of a rapid clinical and electroencephalographic response to intravenous levetiracetam infusion of myoclonic status epilepticus in a patient with progressive myoclonus epilepsy due to Gaucher disease." | 7.78 | Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam. ( Knight, EM; Lenz, T; Tuxhorn, I; Vaca, GF, 2012) |
| "To study the efficacy of levetiracetam (LEV) in the treatment of electrical status epilepticus during sleep (ESES) in children." | 7.78 | [Therapeutic effects of levetiracetam on electrical status epilepticus during sleep in children]. ( Ju, J; Li, XY; Zhang, WN; Zou, LP, 2012) |
| "To report the effectiveness and safety of intravenous levetiracetam in the treatment of children with acute repeated seizures, and status epilepticus in a children's hospital." | 7.78 | Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital. ( Appleton, R; Kneen, R; Kumar, R; McTague, A; Spinty, S, 2012) |
| "Lacosamide has been reported to have been successfully used for non-convulsive status epilepticus after benzodiazepine failure, and convulsive status epilepticus after benzodiazepine and levetiracetam failure." | 7.77 | Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam. ( Chen, LL; Dorsch, A; Haneef, Z; Keselman, I; Stern, JM, 2011) |
| "Case reports suggest lacosamide may have a role in status epilepticus (SE)." | 7.77 | The use of lacosamide in refractory status epilepticus. ( Goodwin, H; Hinson, HE; Karanjia, N; Lewin, JJ; Shermock, KM, 2011) |
| "Phenytoin (PHT), valproic acid (VPA), or levetiracetam (LEV) are commonly used as second-line treatment of status epilepticus (SE), but comparative studies are not available." | 7.77 | Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. ( Alvarez, V; Burnand, B; Januel, JM; Rossetti, AO, 2011) |
| "The objective of this study was to investigate the utility of levetiracetam (LEV) in children with refractory status epilepticus (RSE)." | 7.75 | Levetiracetam in children with refractory status epilepticus. ( Gallentine, WB; Hunnicutt, AS; Husain, AM, 2009) |
| "The purpose of this study was to investigate the safety and efficacy of intravenous levetiracetam (LEV-iv) in refractory status epilepticus (SE)." | 7.75 | Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. ( Bunten, S; Dobis, C; Dogan, M; Dziewas, R; Evers, S; Fischera, M; Happe, S; Kovac, S; Möddel, G; Schäbitz, WR, 2009) |
| "To evaluate the efficacy and tolerability of intravenous (IV) levetiracetam in refractory status epilepticus of migrating partial seizures in infancy (MPSI)." | 7.75 | Intravenous levetiracetam terminates refractory status epilepticus in two patients with migrating partial seizures in infancy. ( Balestri, M; Bianchi, R; Cilio, MR; Di Capua, M; Giovannini, S; Onofri, A; Vigevano, F, 2009) |
| "Since its introduction in 2006, 43 patients with various forms of status epilepticus (SE) have been treated with the intravenous formulation of levetiracetam (LEV) in our clinic." | 7.75 | Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. ( Eue, S; Grumbt, M; Müller, M; Schulze, A, 2009) |
| "To report our experience with the use of intravenous (IV) levetiracetam in patients with status epilepticus who had not responded to IV benzodiazepines." | 7.75 | Experience with intravenous levetiracetam in status epilepticus: a retrospective case series. ( Aristín, JL; Fernández, E; Gámez-Leyva, G; Pascual, J, 2009) |
| "We report a 23-year-old with complex partial status epilepticus, possibly related to underlying stroke-like migraine attacks after radiation therapy syndrome, that was refractory to benzodiazepines and phenytoin but was terminated by administration of intravenous levetiracetam." | 7.75 | Intravenous levetiracetam terminates refractory focal status epilepticus. ( Abend, NS; Dlugos, DJ; Finkel, RS; Florance, N; Licht, DJ, 2009) |
| " In the present study the effects of chronic treatment with levetiracetam were assessed in rats that sustained pilocarpine-induced status epilepticus (SE)." | 7.74 | Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. ( Kaminski, RM; Klitgaard, H; Margineanu, DG; Matagne, A, 2008) |
| "The authors report the case of a child with cerebral palsy and refractory epilepsy who developed nonconvulsive status epilepticus without acute medical cause treated successfully with levetiracetam." | 7.74 | Levetiracetam in nonconvulsive status epilepticus in childhood: a case report. ( Costanza, MC; De Rinaldis, M; Gesualdi, M; Profice, P; Trabacca, A, 2007) |
| "Six patients with status epilepticus (SE) of various etiologies refractory to at least two antiepileptic drugs (AEDs) had complete cessation of their seizures following administration of oral levetiracetam (LEV)." | 7.73 | The use of levetiracetam in refractory status epilepticus. ( Landan, IR; Levin, J; Patel, NC; Szaflarski, J; Wilner, AN, 2006) |
| "To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide." | 7.73 | Nonconvulsive status epilepticus due to ifosfamide. ( Akoglu, H; Aksoy, S; Cakar, M; Erman, M; Kilickap, S; Onal, IK; Tekuzman, G; Tufan, A, 2006) |
| "To assess the anticonvulsant activity of the novel antiepileptic drug, levetiracetam (LEV) in a model of self-sustaining limbic status epilepticus, and to measure the consequence of LEV treatment on the pattern of mitochondrial dysfunction known to occur after status epilepticus (SE)." | 7.73 | Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. ( Cock, HR; Gibbs, JE; Walker, MC, 2006) |
| "We report on a 3-year-old boy with myoclonic-astatic epilepsy who developed myoclonic status epilepticus with continuous twitching of the face and unresponsiveness under monotherapy with levetiracetam." | 7.73 | Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic epilepsy: a case report. ( Krämer, G; Kröll-Seger, J; Mothersill, IW; Novak, S; Sälke-Kellermann, RA, 2006) |
| "Status epilepticus is a condition of prolonged/repetitive seizures that often occurs in the elderly." | 6.75 | Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly. ( Bonini, F; Casciato, S; Di Bonaventura, C; Fattouch, J; Giallonardo, AT; Lapenta, L; Manfredi, M; Petrucci, S; Prencipe, M, 2010) |
| "Levetiracetam (LEV) is a new AED with few side effects." | 6.48 | Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. ( Kumlien, E; Zelano, J, 2012) |
| "The rates of cessation of seizure and prevention of seizure recurrence for 24 h were 84% for phenytoin and 78." | 5.72 | Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. ( Akın, Y; Çağ, Y; Köle, MT; Sager, SG; Zeynel, H, 2022) |
| "Benzodiazepines are used as first-line treatments for status epilepticus." | 5.46 | Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. ( Daidoji, H; Doi, K; Hashimoto, H; Hiruma, T; Inokuchi, R; Morimura, N; Nakamura, K; Naraba, H; Sonoo, T; Tokunaga, K, 2017) |
| "Levetiracetam has broad-spectrum activity in epilepsy." | 5.46 | Levetiracetam-induced thrombocytopenia in a patient with status epilepticus. ( Kim, J; Shin, JW, 2017) |
| "Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy." | 5.43 | Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures. ( Löscher, W; Töllner, K; Twele, F, 2016) |
| "Lacosamide level in milk was low, resulting in an estimated relative infant dose of 1." | 5.42 | Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. ( Ketola, RA; Malm, H; Ruuskanen, JO; Timonen, S; Ylikotila, P, 2015) |
| "Neonatal status epilepticus was successfully controlled with intravenous levetiracetam infusion." | 5.39 | Neonatal status epilepticus controlled with levetiracetam at Sturge Weber syndrome. ( Koroglu, OA; Kultursay, N; Tanriverdi, S; Tekgul, H; Terek, D; Yalaz, M, 2013) |
| "Although the urgency to treat nonconvulsive status epilepticus depends on the underlying illness, most clinicians and authors agree that treatment should be focused to rapidly terminate this condition." | 5.36 | Levetiracetam in nonconvulsive status epilepticus in a child with Angelman syndrome. ( Weber, P, 2010) |
| "Lacosamide (Vimpat) is a newly licensed novel antiepileptic drug." | 5.36 | Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. ( Eggers, C; Hofer, T; Resch, R; Tilz, C, 2010) |
| "Levetiracetam treatment for 25 days, initiated 24 hours after induction of kainate-induced SE, significantly decreased the mean duration of spontaneous EEG seizures 58 days later." | 5.36 | Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus. ( Kato, N; Kudo, K; Maru, E; Shibasaki, T; Sugaya, Y, 2010) |
| " Mean dosage was 1,643 mg/day (range 500-4,000)." | 5.35 | Intravenous levetiracetam for epileptic seizure emergencies in older people. ( Beyenburg, S; Maraite, N; Reuber, M, 2009) |
| "Levetiracetam (LEV) is a novel anticonvulsant available for intravenous (i." | 5.35 | Intravenous levetiracetam as treatment for status epilepticus. ( Berning, S; Boesebeck, F; Kellinghaus, C; van Baalen, A, 2009) |
| "Levetiracetam is an antiepileptic drug that was shown to be effective in various seizure types." | 5.35 | The use of levetiracetam in a child with nonconvulsive status epilepticus. ( Alehan, F; Haberal, M; Ozcay, F, 2008) |
| "Levetiracetam (LEV) is a structurally novel antiepileptic drug (AED) which has demonstrated a broad spectrum of anticonvulsant activities both in experimental and clinical studies." | 5.34 | Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. ( Bethmann, K; Brandt, C; Fedrowitz, M; Gastens, AM; Glien, M; Löscher, W; Potschka, H; Volk, HA, 2007) |
| "Levetiracetam (LEV) has a wide spectrum of action and a favorable pharmacokinetic profile; however, little data exist regarding its use in SE." | 5.33 | Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. ( Bromfield, EB; Rossetti, AO, 2005) |
| "The use of new antiepileptic drugs for treatment of status epilepticus (SE) has not been studied systematically, particularly with respect to response predictors, the possibility of a dose-response relationship, and the efficacy of administration through a nasogastric tube." | 5.33 | Determinants of success in the use of oral levetiracetam in status epilepticus. ( Bromfield, EB; Rossetti, AO, 2006) |
| "Minimum plasma levetiracetam concentration can be reached after rectal administration of 40 mg/kg in dogs affected by cluster seizures and status epilepticus and concurrently receiving other antiepileptic drugs." | 5.27 | Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus. ( Amedeo, S; Bertone, I; Cagnotti, G; D'Angelo, A; Dappiano, E; Gardini, G; Guerriero, G; Lentini, L; Odore, R, 2018) |
| "IV Levetiracetam controls status epilepticus or cluster seizures with an efficacy comparable to that of phenytoin." | 5.24 | Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study. ( Al-Amrani, K; Al-Asmi, A; Al-Hashim, A; Ganguly, SS; Gujjar, AR; Jacob, PC; Nandhagopal, R, 2017) |
| "We report the efficacy and safety of lorazepam (LOR), phenytoin (PHT), valproate (VPA) and levetiracetam (LEV) as first and second choice antiepileptic drug (AED) in status epilepticus (SE) and their combinations in preventing refractory SE." | 5.22 | A comparison of four antiepileptic drugs in status epilepticus: experience from India. ( Kalita, J; Misra, UK, 2016) |
| "The purpose of this study was to compare safety and efficacy of intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) in management of status epilepticus (SE)." | 5.20 | Levetiracetam versus phenytoin in management of status epilepticus. ( Bhalla, A; Chakravarthi, S; Goyal, MK; Modi, M; Singh, P, 2015) |
| "Levetiracetam is effective in individuals with electrical status epilepticus during sleep with tolerable side effects." | 5.19 | Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience. ( Cai, FC; Chen, X; Chen, XQ; Gao, L; Huang, SP; Pang, BD; Yang, ZX; Zhang, WN; Zhao, M; Zou, LP, 2014) |
| "We performed a double-blind placebo-controlled crossover study of the effects of spike activity during sleep and when awake on learning, long-term memory, vigilance and behavior before and after treatment with levetiracetam in children with electrical status epilepticus during sleep." | 5.17 | Subclinical epileptiform activity in children with electrical status epilepticus during sleep: effects on cognition and behavior before and after treatment with levetiracetam. ( Bakke, KA; Bjørnæs, H; Brager-Larsen, LM; Eriksson, AS; Heminghyt, E; Larsson, PG; Rytter, E, 2013) |
| "For the management of status epilepticus (SE), lorazepam (LOR) is recommended as the first and phenytoin or fosphenytoin as the second choice." | 5.16 | Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. ( Kalita, J; Maurya, PK; Misra, UK, 2012) |
| "To evaluate the feasibility and safety of intravenous (iv) levetiracetam (LEV) added to the standard therapeutic regimen in adults with status epilepticus (SE), and as secondary objective to assess a population pharmacokinetic (PK) model for ivLEV in patients with SE." | 5.14 | Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus. ( Engelsman, J; Peeters, E; Touw, DJ; Uges, JW; van Huizen, MD; Vecht, CJ; Wilms, EB, 2009) |
| "The objective of the study was to perform a systematic review and meta-analysis to evaluate the efficacy and safety of levetiracetam (LEV) or phenytoin (PHT) as second-line treatment for status epilepticus (SE)." | 5.05 | Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis. ( DeMott, JM; Gottlieb, M; Peksa, GD; Slocum, GW, 2020) |
| "Over last fifty years, intravenous (iv) phenytoin (PHT) loading dose has been the treatment of choice for patients with benzodiazepine-resistant convulsive status epilepticus and several guidelines recommended this treatment regimen with simultaneous iv diazepam." | 4.98 | Why we prefer levetiracetam over phenytoin for treatment of status epilepticus. ( Amantini, A; Campostrini, R; Giannasi, G; Giorgi, FS; Giovannelli, F; Nazerian, P; Paganini, M; Zaccara, G, 2018) |
| "The aim of this study was to conduct a meta-analysis of published studies to directly compare intravenous (IV) levetiracetam (LEV) with IV phenytoin (PHT) or IV valproate (VPA) as second-line treatment of status epilepticus (SE), to indirectly compare intravenous IV LEV with IV VPA using common reference-based indirect comparison meta-analysis, and to verify whether results of indirect comparisons are consistent with results of head-to-head randomized controlled trials (RCTs) directly comparing IV LEV with IV VPA." | 4.93 | Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. ( Bragazzi, N; Brigo, F; Nardone, R; Trinka, E, 2016) |
| "Recommended loading doses of levetiracetam (LEV) for status epilepticus (SE) treatment have increased over time." | 4.31 | Status epilepticus prognosis following levetiracetam administration: Analysis of loading doses. ( Kuffer, I; Novy, J; Rossetti, AO, 2023) |
| "Levetiracetam (LEV) suppresses the upregulation of proinflammatory molecules that occurs during epileptogenesis after status epilepticus (SE)." | 4.12 | Regulation of Inflammation-Related Genes through ( Hashimoto, R; Ishihara, Y; Itoh, K; Komori, R; Kono, T; Kozawa, C; Kubo, S; Matsuo, T; Yokota-Nakatsuma, A, 2022) |
| "We aimed to evaluate the blood concentration of levetiracetam (LEV), as a second-line drug, in patients with status epilepticus (SE) in an emergency clinical setting." | 4.02 | Blood concentration of levetiracetam after bolus administration in patients with status epilepticus. ( Hotta, M; Kaneko, J; Kondo, M; Kubota, M; Kuno, M; Nagano, M; Sugaya, K; Tagami, T; Takase, H; Unemoto, K, 2021) |
| "Because of the lack of studies comparing the efficacy and safety of levetiracetam and valproate before the induction of general anesthesia in the treatment of convulsive refractory status epilepticus in children, we aimed to compare the effectiveness of these antiepileptic drugs in patients with convulsive status epilepticus admitted to the Pediatric Intensive Care Unit between 2011 and 2014." | 3.83 | A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children. ( Ağın, H; Ceylan, G; Güzel, O; İşgüder, R; Yılmaz, Ü, 2016) |
| "Our previous study showed that treatment with levetiracetam (LEV) after status epilepticus (SE) termination by diazepam might prevent the development of spontaneous recurrent seizures via the inhibition of neurotoxicity induced by brain edema events." | 3.83 | Levetiracetam treatment influences blood-brain barrier failure associated with angiogenesis and inflammatory responses in the acute phase of epileptogenesis in post-status epilepticus mice. ( Chiba, Y; Dohgu, S; Ishihara, Y; Itoh, K; Kataoka, Y; Komori, R; Nochi, H; Takata-Tsuji, F; Taniguchi, R; Ueno, M, 2016) |
| "To clarify the effect of levetiracetam (LEV) for acute and chronic seizure control in acute encephalitis with refractory, repetitive partial seizures (AERRPS)." | 3.81 | Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase. ( Imamura, A; Maegaki, Y; Maruta, K; Matsunami, K; Narita, A; Nishimura, Y; Ohno, K; Saiki, Y; Saito, Y; Sokota, T; Sugihara, S; Tamasaki, A; Ueda, R, 2015) |
| "To investigate the antiepileptic and protective effects of intravenous levetiracetam (iv LEV) in the rhesus monkey model of acute status epilepticus (SE)." | 3.81 | Pretreatment with intravenous levetiracetam in the rhesus monkey Coriaria lactone-induced status epilepticus model. ( Chen, F; Chen, SH; Cheng, L; Hong, Z; Lei, S; Li, HX; Li, JM; Li, L; Yang, TH; Zhou, D, 2015) |
| "Epilepsy with electrical status epilepticus in sleep (ESES) is a devastating disease, and we sought to evaluate the efficacy of levetiracetam (LEV) for the treatment of patients with this epileptic encephalopathy in China." | 3.81 | Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep. ( Cai, F; Chen, J; Feng, C; Hu, Y; Jiang, L, 2015) |
| "Intravenous levetiracetam is an option for treatment of status epilepticus (SE) and acute repetitive seizures (ARS)." | 3.81 | Intravenous levetiracetam in Thai children and adolescents with status epilepticus and acute repetitive seizures. ( Khongkhatithum, C; Thampratankul, L; Visudtibhan, A; Wiwattanadittakul, N, 2015) |
| "To assess the efficacy of intravenous (IV) levetiracetam (LEV) in the treatment of status epilepticus (SE) and treatment outcomes." | 3.81 | Intravenous levetiracetam treatment in status epilepticus: A prospective study. ( Atmaca, MM; Bebek, N; Gurses, C; Orhan, EK, 2015) |
| " Diazepam produced a dose-dependent protection against 6-Hz seizures in control and pilocarpine mice, both at 2 weeks and 8 weeks after SE, but with a more pronounced increase in potency in post-SE animals at 2 weeks." | 3.81 | Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model. ( Kaminski, RM; Leclercq, K, 2015) |
| "To compare intravenous phenytoin (PHT) and intravenous lacosamide (LCM) for treatment of status epilepticus after failure of the first and second drug." | 3.80 | Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. ( Berning, S; Kellinghaus, C; Stögbauer, F, 2014) |
| "Intravenous levetiracetam (LEV) has been shown to be effective and safe in treating adults with refractory status epilepticus (SE)." | 3.80 | Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus. ( Chae, JH; Choi, J; Hwang, H; Hwang, YS; Kim, H; Kim, JS; Kim, KJ; Lee, JH; Lim, BC; Ryu, HW, 2014) |
| "To study the efficacy of levetiracetam (LEV) combined with short-term clonazepam (CZP) in the treatment of electrical status epilepticus during sleep (ESES) in children with benign childhood epilepsy with centrotemporal spikes (BECCT)." | 3.80 | [Efficacy of levetiracetam combined with short-term clonazepam in treatment of electrical status epilepticus during sleep in children with benign childhood epilepsy with centrotemporal spikes]. ( Chen, L; Su, TF; Xu, SQ, 2014) |
| "Levetiracetam has been reported to be well tolerated and effective in status epilepticus (SE) refractory to benzodiazepine." | 3.79 | The effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampus. ( Choi, HC; Kang, TC; Kim, JE; Kim, YI; Lee, DS; Ryu, HJ; Song, HK, 2013) |
| " Approximately 30-40% of brain tumors patients who present with status epilepticus (SE) will not respond to typical therapy consisting of benzodiazepines and phenytoin (PHT), resulting in patients with refractory status epilepticus (RSE)." | 3.78 | Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors. ( Doreswamy, M; Gingrich, KJ; Kolls, BJ; Swisher, CB; Vredenburgh, JJ, 2012) |
| "We present the first reported case of a rapid clinical and electroencephalographic response to intravenous levetiracetam infusion of myoclonic status epilepticus in a patient with progressive myoclonus epilepsy due to Gaucher disease." | 3.78 | Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam. ( Knight, EM; Lenz, T; Tuxhorn, I; Vaca, GF, 2012) |
| "To study the efficacy of levetiracetam (LEV) in the treatment of electrical status epilepticus during sleep (ESES) in children." | 3.78 | [Therapeutic effects of levetiracetam on electrical status epilepticus during sleep in children]. ( Ju, J; Li, XY; Zhang, WN; Zou, LP, 2012) |
| "To report the effectiveness and safety of intravenous levetiracetam in the treatment of children with acute repeated seizures, and status epilepticus in a children's hospital." | 3.78 | Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital. ( Appleton, R; Kneen, R; Kumar, R; McTague, A; Spinty, S, 2012) |
| "Lacosamide has been reported to have been successfully used for non-convulsive status epilepticus after benzodiazepine failure, and convulsive status epilepticus after benzodiazepine and levetiracetam failure." | 3.77 | Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam. ( Chen, LL; Dorsch, A; Haneef, Z; Keselman, I; Stern, JM, 2011) |
| "Case reports suggest lacosamide may have a role in status epilepticus (SE)." | 3.77 | The use of lacosamide in refractory status epilepticus. ( Goodwin, H; Hinson, HE; Karanjia, N; Lewin, JJ; Shermock, KM, 2011) |
| "Phenytoin (PHT), valproic acid (VPA), or levetiracetam (LEV) are commonly used as second-line treatment of status epilepticus (SE), but comparative studies are not available." | 3.77 | Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. ( Alvarez, V; Burnand, B; Januel, JM; Rossetti, AO, 2011) |
| " We previously showed that tolerance to levetiracetam (LEV) developed within 4 days after the start of the treatment in a rat model for spontaneous seizures after electrically induced status epilepticus." | 3.76 | Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats. ( Edelbroek, PM; Gorter, JA; van Vliet, EA, 2010) |
| "The objective of this study was to investigate the utility of levetiracetam (LEV) in children with refractory status epilepticus (RSE)." | 3.75 | Levetiracetam in children with refractory status epilepticus. ( Gallentine, WB; Hunnicutt, AS; Husain, AM, 2009) |
| "The purpose of this study was to investigate the safety and efficacy of intravenous levetiracetam (LEV-iv) in refractory status epilepticus (SE)." | 3.75 | Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus. ( Bunten, S; Dobis, C; Dogan, M; Dziewas, R; Evers, S; Fischera, M; Happe, S; Kovac, S; Möddel, G; Schäbitz, WR, 2009) |
| "To evaluate the efficacy and tolerability of intravenous (IV) levetiracetam in refractory status epilepticus of migrating partial seizures in infancy (MPSI)." | 3.75 | Intravenous levetiracetam terminates refractory status epilepticus in two patients with migrating partial seizures in infancy. ( Balestri, M; Bianchi, R; Cilio, MR; Di Capua, M; Giovannini, S; Onofri, A; Vigevano, F, 2009) |
| "Since its introduction in 2006, 43 patients with various forms of status epilepticus (SE) have been treated with the intravenous formulation of levetiracetam (LEV) in our clinic." | 3.75 | Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. ( Eue, S; Grumbt, M; Müller, M; Schulze, A, 2009) |
| "To report our experience with the use of intravenous (IV) levetiracetam in patients with status epilepticus who had not responded to IV benzodiazepines." | 3.75 | Experience with intravenous levetiracetam in status epilepticus: a retrospective case series. ( Aristín, JL; Fernández, E; Gámez-Leyva, G; Pascual, J, 2009) |
| "We report a 23-year-old with complex partial status epilepticus, possibly related to underlying stroke-like migraine attacks after radiation therapy syndrome, that was refractory to benzodiazepines and phenytoin but was terminated by administration of intravenous levetiracetam." | 3.75 | Intravenous levetiracetam terminates refractory focal status epilepticus. ( Abend, NS; Dlugos, DJ; Finkel, RS; Florance, N; Licht, DJ, 2009) |
| " In the present study the effects of chronic treatment with levetiracetam were assessed in rats that sustained pilocarpine-induced status epilepticus (SE)." | 3.74 | Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats. ( Kaminski, RM; Klitgaard, H; Margineanu, DG; Matagne, A, 2008) |
| "The authors report the case of a child with cerebral palsy and refractory epilepsy who developed nonconvulsive status epilepticus without acute medical cause treated successfully with levetiracetam." | 3.74 | Levetiracetam in nonconvulsive status epilepticus in childhood: a case report. ( Costanza, MC; De Rinaldis, M; Gesualdi, M; Profice, P; Trabacca, A, 2007) |
| "Six patients with status epilepticus (SE) of various etiologies refractory to at least two antiepileptic drugs (AEDs) had complete cessation of their seizures following administration of oral levetiracetam (LEV)." | 3.73 | The use of levetiracetam in refractory status epilepticus. ( Landan, IR; Levin, J; Patel, NC; Szaflarski, J; Wilner, AN, 2006) |
| "To report 2 cases of nonconvulsive status epilepticus (NCSE) following infusion of ifosfamide." | 3.73 | Nonconvulsive status epilepticus due to ifosfamide. ( Akoglu, H; Aksoy, S; Cakar, M; Erman, M; Kilickap, S; Onal, IK; Tekuzman, G; Tufan, A, 2006) |
| "To assess the anticonvulsant activity of the novel antiepileptic drug, levetiracetam (LEV) in a model of self-sustaining limbic status epilepticus, and to measure the consequence of LEV treatment on the pattern of mitochondrial dysfunction known to occur after status epilepticus (SE)." | 3.73 | Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. ( Cock, HR; Gibbs, JE; Walker, MC, 2006) |
| "We report on a 3-year-old boy with myoclonic-astatic epilepsy who developed myoclonic status epilepticus with continuous twitching of the face and unresponsiveness under monotherapy with levetiracetam." | 3.73 | Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic epilepsy: a case report. ( Krämer, G; Kröll-Seger, J; Mothersill, IW; Novak, S; Sälke-Kellermann, RA, 2006) |
| "The objective of the study was to analyze the short-term efficacy and safety of levetiracetam (LEV) to treat repetitive seizures in hospitalized patients." | 3.73 | Use of levetiracetam in hospitalized patients. ( Amaro, S; Carreño, M; Delgado, R; Donaire, A; Falip, M; Maestro, I; Toledo, M, 2006) |
| "Current treatment of human status epilepticus (SE) relies on drugs developed for chronic treatment of epilepsy." | 2.76 | Canine status epilepticus: a translational platform for human therapeutic trials. ( Cloyd, JC; Coles, LD; Craft, EM; Leppik, IE; Patterson, EN, 2011) |
| "Therapeutic strategies for patients with generalized convulsive status epilepticus (GCSE) need to be improved." | 2.76 | A prehospital randomized trial in convulsive status epilepticus. ( An, K; Baulac, M; Bolgert, F; Carli, P; Dagron, C; Demeret, S; Lamhaut, L; Navarro, V, 2011) |
| "Status epilepticus is a condition of prolonged/repetitive seizures that often occurs in the elderly." | 2.75 | Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly. ( Bonini, F; Casciato, S; Di Bonaventura, C; Fattouch, J; Giallonardo, AT; Lapenta, L; Manfredi, M; Petrucci, S; Prencipe, M, 2010) |
| "Convulsive status epilepticus is the most extreme form of seizure." | 2.55 | Review and update of the Hong Kong Epilepsy Guideline on status epilepticus. ( Fung, BB; Fung, EL, 2017) |
| "A meta-analysis found higher rates of seizure cessation with valproate 75." | 2.53 | Pharmacologic treatment of status epilepticus. ( Brigo, F; Höfler, J; Kalss, G; Leitinger, M; Rohracher, A; Trinka, E, 2016) |
| "Acute seizure and status epilepticus constitute one of the major medical emergencies in children." | 2.48 | Management of acute seizure and status epilepticus in pediatric emergency. ( Sasidaran, K; Singhi, P; Singhi, S, 2012) |
| "Levetiracetam (LEV) is a new AED with few side effects." | 2.48 | Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. ( Kumlien, E; Zelano, J, 2012) |
| " For each class, the dosing scheme and practical issues related to administration are described, based on evidence when available in the literature." | 2.45 | [Drugs for status epilepticus treatment]. ( Mazoit, JX; Navarro, V, 2009) |
| "The rates of cessation of seizure and prevention of seizure recurrence for 24 h were 84% for phenytoin and 78." | 1.72 | Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children. ( Akın, Y; Çağ, Y; Köle, MT; Sager, SG; Zeynel, H, 2022) |
| "Levetiracetam (LEV) is an urgent control antiepileptic medication that offers relative lack of adverse effects and ease of monitoring." | 1.62 | Rapid administration of undiluted intravenous levetiracetam. ( Bonnin, S; Haller, JT; Radosevich, J, 2021) |
| " Criterion 2=the last drug introduced into the antiepileptic therapy within 72h before the cessation of SE and without changes in dosage or number of the co-medication." | 1.46 | The efficacy of different kinds of intravenously applied antiepileptic drugs in the treatment of status epilepticus. How can it be determined? ( Redecker, J; Rösche, J; Wittstock, M, 2017) |
| "Benzodiazepines are used as first-line treatments for status epilepticus." | 1.46 | Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus. ( Daidoji, H; Doi, K; Hashimoto, H; Hiruma, T; Inokuchi, R; Morimura, N; Nakamura, K; Naraba, H; Sonoo, T; Tokunaga, K, 2017) |
| "Levetiracetam has broad-spectrum activity in epilepsy." | 1.46 | Levetiracetam-induced thrombocytopenia in a patient with status epilepticus. ( Kim, J; Shin, JW, 2017) |
| "Recently, the use of acute seizure tests in epileptic rats or mice has been proposed as a novel strategy for evaluating novel AEDs for increased antiseizure efficacy." | 1.43 | Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures. ( Löscher, W; Töllner, K; Twele, F, 2016) |
| "Lacosamide level in milk was low, resulting in an estimated relative infant dose of 1." | 1.42 | Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy. ( Ketola, RA; Malm, H; Ruuskanen, JO; Timonen, S; Ylikotila, P, 2015) |
| "The seizures were unresponsive to bolus midazolam, phenytoin infusion and levetiracetam infusion." | 1.42 | A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature. ( Çelik, T; Çelik, Ü; Gezgin, AE; Kaya, MS; Kömür, M; Tolunay, O, 2015) |
| " Collected data included age, gender, diagnosis on admission, dosing regimen, documented seizure activity, adverse reactions, concomitant use of other antiepileptic drugs, and condition on discharge." | 1.40 | The safety and tolerability of different intravenous administrations of levetiracetam, bolus versus infusion, in intensive care unit patients. ( Bashir, S; Burakgazi, E; Doss, V; Pellock, J, 2014) |
| "53." | 1.39 | Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs. ( Buniak, L; Henry, JC; Mohile, N; Wang, H; Wychowski, T, 2013) |
| "Neonatal status epilepticus was successfully controlled with intravenous levetiracetam infusion." | 1.39 | Neonatal status epilepticus controlled with levetiracetam at Sturge Weber syndrome. ( Koroglu, OA; Kultursay, N; Tanriverdi, S; Tekgul, H; Terek, D; Yalaz, M, 2013) |
| "Pentobarbital was chosen later in the therapy for all ages." | 1.39 | Treatment of status epilepticus: an international survey of experts. ( Alldredge, B; Bell, R; Bleck, TP; Brophy, GM; Claassen, J; Glauser, T; LaRoche, SM; Riviello, JJ; Shutter, L; Sperling, MR; Treiman, DM; Vespa, PM, 2013) |
| "Status epilepticus is a common neurological emergency in childhood and associated with significant morbidity and mortality." | 1.37 | Status epilepticus. ( Gulati, S; Lodha, R; Raj, D, 2011) |
| "Although the urgency to treat nonconvulsive status epilepticus depends on the underlying illness, most clinicians and authors agree that treatment should be focused to rapidly terminate this condition." | 1.36 | Levetiracetam in nonconvulsive status epilepticus in a child with Angelman syndrome. ( Weber, P, 2010) |
| "Lacosamide (Vimpat) is a newly licensed novel antiepileptic drug." | 1.36 | Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide. ( Eggers, C; Hofer, T; Resch, R; Tilz, C, 2010) |
| "Levetiracetam treatment for 25 days, initiated 24 hours after induction of kainate-induced SE, significantly decreased the mean duration of spontaneous EEG seizures 58 days later." | 1.36 | Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus. ( Kato, N; Kudo, K; Maru, E; Shibasaki, T; Sugaya, Y, 2010) |
| " Mean dosage was 1,643 mg/day (range 500-4,000)." | 1.35 | Intravenous levetiracetam for epileptic seizure emergencies in older people. ( Beyenburg, S; Maraite, N; Reuber, M, 2009) |
| "Levetiracetam (LEV) is a novel anticonvulsant available for intravenous (i." | 1.35 | Intravenous levetiracetam as treatment for status epilepticus. ( Berning, S; Boesebeck, F; Kellinghaus, C; van Baalen, A, 2009) |
| "Status epilepticus is defined as a seizure lasting beyond 30 minutes." | 1.35 | Role of intravenous levetiracetam in acute seizure management of children. ( Crisp, ED; Kayani, S; Kirmani, BF; Rajab, H, 2009) |
| "Levetiracetam is an antiepileptic drug that was shown to be effective in various seizure types." | 1.35 | The use of levetiracetam in a child with nonconvulsive status epilepticus. ( Alehan, F; Haberal, M; Ozcay, F, 2008) |
| "Levetiracetam (LEV) is a structurally novel antiepileptic drug (AED) which has demonstrated a broad spectrum of anticonvulsant activities both in experimental and clinical studies." | 1.34 | Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats. ( Bethmann, K; Brandt, C; Fedrowitz, M; Gastens, AM; Glien, M; Löscher, W; Potschka, H; Volk, HA, 2007) |
| "Levetiracetam (LEV) has a wide spectrum of action and a favorable pharmacokinetic profile; however, little data exist regarding its use in SE." | 1.33 | Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. ( Bromfield, EB; Rossetti, AO, 2005) |
| "The use of new antiepileptic drugs for treatment of status epilepticus (SE) has not been studied systematically, particularly with respect to response predictors, the possibility of a dose-response relationship, and the efficacy of administration through a nasogastric tube." | 1.33 | Determinants of success in the use of oral levetiracetam in status epilepticus. ( Bromfield, EB; Rossetti, AO, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 45 (33.33) | 29.6817 |
| 2010's | 82 (60.74) | 24.3611 |
| 2020's | 8 (5.93) | 2.80 |
| Authors | Studies |
|---|---|
| Reinert, JP | 1 |
| Maktabi, L | 1 |
| Branam, D | 1 |
| Snyder, M | 1 |
| Köle, MT | 1 |
| Sager, SG | 1 |
| Zeynel, H | 1 |
| Çağ, Y | 1 |
| Akın, Y | 1 |
| Komori, R | 2 |
| Matsuo, T | 1 |
| Yokota-Nakatsuma, A | 1 |
| Hashimoto, R | 1 |
| Kubo, S | 1 |
| Kozawa, C | 1 |
| Kono, T | 1 |
| Ishihara, Y | 3 |
| Itoh, K | 3 |
| Kandeda, AK | 1 |
| Nodeina, S | 1 |
| Mabou, ST | 1 |
| Kuffer, I | 1 |
| Novy, J | 2 |
| Rossetti, AO | 5 |
| DeMott, JM | 1 |
| Slocum, GW | 1 |
| Gottlieb, M | 1 |
| Peksa, GD | 1 |
| Nagano, M | 1 |
| Tagami, T | 1 |
| Kaneko, J | 1 |
| Kondo, M | 1 |
| Hotta, M | 1 |
| Kubota, M | 1 |
| Sugaya, K | 1 |
| Takase, H | 1 |
| Kuno, M | 1 |
| Unemoto, K | 1 |
| Haller, JT | 1 |
| Bonnin, S | 1 |
| Radosevich, J | 1 |
| Redecker, J | 1 |
| Wittstock, M | 1 |
| Rösche, J | 3 |
| Verrotti, A | 1 |
| Ambrosi, M | 1 |
| Pavone, P | 1 |
| Striano, P | 1 |
| Gujjar, AR | 1 |
| Nandhagopal, R | 1 |
| Jacob, PC | 1 |
| Al-Hashim, A | 1 |
| Al-Amrani, K | 1 |
| Ganguly, SS | 1 |
| Al-Asmi, A | 1 |
| Lyttle, MD | 1 |
| Gamble, C | 1 |
| Messahel, S | 1 |
| Hickey, H | 1 |
| Iyer, A | 1 |
| Woolfall, K | 1 |
| Humphreys, A | 1 |
| Bacon, NEA | 1 |
| Roper, L | 1 |
| Babl, FE | 2 |
| Dalziel, SR | 2 |
| Ryan, M | 1 |
| Appleton, RE | 1 |
| Nakamura, K | 1 |
| Inokuchi, R | 1 |
| Daidoji, H | 1 |
| Naraba, H | 1 |
| Sonoo, T | 1 |
| Hashimoto, H | 1 |
| Tokunaga, K | 1 |
| Hiruma, T | 1 |
| Doi, K | 1 |
| Morimura, N | 1 |
| Furyk, J | 1 |
| Bonisch, M | 1 |
| Oakley, E | 1 |
| Borland, M | 1 |
| Neutze, J | 1 |
| Donath, S | 1 |
| Sharpe, C | 1 |
| Harvey, S | 1 |
| Davidson, A | 1 |
| Craig, S | 1 |
| Phillips, N | 1 |
| George, S | 1 |
| Rao, A | 1 |
| Cheng, N | 1 |
| Zhang, M | 1 |
| Sinn, K | 1 |
| Kochar, A | 1 |
| Brabyn, C | 1 |
| Gillinder, L | 1 |
| Lehn, A | 1 |
| Brown, H | 1 |
| Dionisio, S | 1 |
| Zaccara, G | 1 |
| Giorgi, FS | 1 |
| Amantini, A | 1 |
| Giannasi, G | 1 |
| Campostrini, R | 1 |
| Giovannelli, F | 1 |
| Paganini, M | 1 |
| Nazerian, P | 1 |
| Cagnotti, G | 1 |
| Odore, R | 1 |
| Gardini, G | 1 |
| Amedeo, S | 1 |
| Bertone, I | 1 |
| Guerriero, G | 1 |
| Lentini, L | 1 |
| Dappiano, E | 1 |
| D'Angelo, A | 1 |
| Lee, DS | 1 |
| Ryu, HJ | 1 |
| Kim, JE | 1 |
| Choi, HC | 1 |
| Kim, YI | 1 |
| Song, HK | 1 |
| Kang, TC | 1 |
| Connor, JT | 1 |
| Elm, JJ | 1 |
| Broglio, KR | 1 |
| Ohe, Y | 1 |
| Hayashi, T | 1 |
| Deguchi, I | 1 |
| Fukuoka, T | 1 |
| Maruyama, H | 1 |
| Kato, Y | 1 |
| Tanahashi, N | 1 |
| Kellinghaus, C | 3 |
| Berning, S | 2 |
| Stögbauer, F | 1 |
| Bleck, T | 1 |
| Cock, H | 1 |
| Chamberlain, J | 1 |
| Cloyd, J | 1 |
| Connor, J | 1 |
| Elm, J | 1 |
| Fountain, N | 1 |
| Jones, E | 1 |
| Lowenstein, D | 1 |
| Shinnar, S | 1 |
| Silbergleit, R | 1 |
| Treiman, D | 1 |
| Trinka, E | 6 |
| Kapur, J | 1 |
| Wychowski, T | 1 |
| Wang, H | 1 |
| Buniak, L | 1 |
| Henry, JC | 1 |
| Mohile, N | 1 |
| Chen, XQ | 1 |
| Zhang, WN | 2 |
| Yang, ZX | 1 |
| Zhao, M | 1 |
| Cai, FC | 1 |
| Huang, SP | 1 |
| Gao, L | 1 |
| Pang, BD | 1 |
| Chen, X | 1 |
| Zou, LP | 2 |
| Burakgazi, E | 1 |
| Bashir, S | 1 |
| Doss, V | 1 |
| Pellock, J | 1 |
| Kim, JS | 1 |
| Lee, JH | 1 |
| Ryu, HW | 1 |
| Lim, BC | 1 |
| Hwang, H | 1 |
| Chae, JH | 1 |
| Choi, J | 1 |
| Kim, KJ | 1 |
| Hwang, YS | 1 |
| Kim, H | 1 |
| Su, TF | 1 |
| Xu, SQ | 1 |
| Chen, L | 1 |
| Ueda, R | 1 |
| Saito, Y | 1 |
| Ohno, K | 1 |
| Maruta, K | 1 |
| Matsunami, K | 1 |
| Saiki, Y | 1 |
| Sokota, T | 1 |
| Sugihara, S | 1 |
| Nishimura, Y | 1 |
| Tamasaki, A | 1 |
| Narita, A | 1 |
| Imamura, A | 1 |
| Maegaki, Y | 1 |
| Cheng, L | 1 |
| Lei, S | 1 |
| Chen, SH | 1 |
| Hong, Z | 1 |
| Yang, TH | 1 |
| Li, L | 1 |
| Chen, F | 1 |
| Li, HX | 1 |
| Zhou, D | 1 |
| Li, JM | 1 |
| Chen, J | 1 |
| Cai, F | 1 |
| Jiang, L | 1 |
| Hu, Y | 1 |
| Feng, C | 1 |
| Inamine, M | 1 |
| Oshima, W | 1 |
| Kotani, M | 1 |
| Chiba, Y | 2 |
| Ueno, M | 2 |
| Inoue, S | 1 |
| Yazawa, S | 1 |
| Murahara, T | 1 |
| Yamauchi, R | 1 |
| Shimohama, S | 1 |
| Khongkhatithum, C | 1 |
| Thampratankul, L | 1 |
| Wiwattanadittakul, N | 1 |
| Visudtibhan, A | 1 |
| Chakravarthi, S | 1 |
| Goyal, MK | 1 |
| Modi, M | 1 |
| Bhalla, A | 1 |
| Singh, P | 1 |
| Lang, N | 1 |
| Esser, W | 1 |
| Evers, S | 2 |
| Nguento, A | 1 |
| Schlegel, U | 1 |
| Gaida, B | 1 |
| Gburek-Augustat, J | 1 |
| Altenmüller, DM | 2 |
| Burghaus, L | 1 |
| Hoffmann, F | 1 |
| Fiedler, B | 1 |
| Bast, T | 1 |
| Rehfeld, T | 1 |
| Happe, S | 2 |
| Seitz, RJ | 1 |
| Boor, R | 1 |
| Stephani, U | 1 |
| Atmaca, MM | 1 |
| Orhan, EK | 1 |
| Bebek, N | 1 |
| Gurses, C | 1 |
| Mundlamuri, RC | 1 |
| Sinha, S | 1 |
| Subbakrishna, DK | 1 |
| Prathyusha, PV | 1 |
| Nagappa, M | 1 |
| Bindu, PS | 1 |
| Taly, AB | 1 |
| Umamaheswara Rao, GS | 1 |
| Satishchandra, P | 1 |
| Leclercq, K | 2 |
| Kaminski, RM | 3 |
| Ylikotila, P | 1 |
| Ketola, RA | 1 |
| Timonen, S | 1 |
| Malm, H | 1 |
| Ruuskanen, JO | 1 |
| Tolunay, O | 1 |
| Çelik, T | 1 |
| Kömür, M | 1 |
| Gezgin, AE | 1 |
| Kaya, MS | 1 |
| Çelik, Ü | 1 |
| Dömötör, J | 1 |
| Clemens, B | 1 |
| Zheng, F | 1 |
| Du, C | 1 |
| Wang, X | 1 |
| Misra, UK | 2 |
| Kalita, J | 2 |
| Karlov, VA | 1 |
| Vlasov, PN | 1 |
| Gladov, BP | 1 |
| Kamelkova, EG | 1 |
| Claassen, J | 3 |
| Navarro, V | 3 |
| Dagron, C | 2 |
| Elie, C | 1 |
| Lamhaut, L | 2 |
| Demeret, S | 2 |
| Urien, S | 1 |
| An, K | 2 |
| Bolgert, F | 2 |
| Tréluyer, JM | 1 |
| Baulac, M | 2 |
| Carli, P | 2 |
| Höfler, J | 1 |
| Leitinger, M | 1 |
| Rohracher, A | 1 |
| Kalss, G | 1 |
| Brigo, F | 2 |
| Paschen, I | 1 |
| Walter, U | 2 |
| Kamm, C | 1 |
| Sonis, J | 1 |
| Borczuk, P | 1 |
| Ptak, T | 1 |
| Miller, ES | 1 |
| Töllner, K | 1 |
| Twele, F | 1 |
| Löscher, W | 2 |
| İşgüder, R | 1 |
| Güzel, O | 1 |
| Ceylan, G | 1 |
| Yılmaz, Ü | 1 |
| Ağın, H | 1 |
| Datta, P | 1 |
| Hope, O | 1 |
| Kalamangalam, GP | 1 |
| Nochi, H | 1 |
| Taniguchi, R | 1 |
| Takata-Tsuji, F | 1 |
| Dohgu, S | 1 |
| Kataoka, Y | 1 |
| Bragazzi, N | 1 |
| Nardone, R | 1 |
| Fung, EL | 1 |
| Fung, BB | 1 |
| Kim, J | 1 |
| Shin, JW | 1 |
| Kühn, A | 1 |
| Surges, R | 1 |
| Schulze-Bonhage, A | 2 |
| Zenkov, LR | 1 |
| Shevtsov, KI | 1 |
| Gubanova, NB | 1 |
| van Vliet, EA | 2 |
| Aronica, E | 1 |
| Redeker, S | 1 |
| Boer, K | 1 |
| Gorter, JA | 2 |
| Margineanu, DG | 1 |
| Matagne, A | 2 |
| Klitgaard, H | 2 |
| Gallentine, WB | 1 |
| Hunnicutt, AS | 1 |
| Husain, AM | 1 |
| Beyenburg, S | 1 |
| Reuber, M | 1 |
| Maraite, N | 1 |
| Haberlandt, E | 1 |
| Sigl, SB | 1 |
| Scholl-Buergi, S | 1 |
| Karall, D | 1 |
| Rauchenzauner, M | 1 |
| Rostásy, K | 1 |
| Uges, JW | 1 |
| van Huizen, MD | 1 |
| Engelsman, J | 1 |
| Wilms, EB | 1 |
| Touw, DJ | 1 |
| Peeters, E | 1 |
| Vecht, CJ | 1 |
| Wheless, JW | 1 |
| Treiman, DM | 2 |
| Carota, A | 1 |
| Mazoit, JX | 1 |
| Abend, NS | 2 |
| Monk, HM | 1 |
| Licht, DJ | 2 |
| Dlugos, DJ | 2 |
| Elouni, B | 1 |
| Ben Salem, C | 1 |
| Biour, M | 1 |
| García, C | 1 |
| Rubio, G | 1 |
| Möddel, G | 1 |
| Bunten, S | 1 |
| Dobis, C | 1 |
| Kovac, S | 1 |
| Dogan, M | 1 |
| Fischera, M | 1 |
| Dziewas, R | 1 |
| Schäbitz, WR | 1 |
| Boesebeck, F | 1 |
| van Baalen, A | 1 |
| Kirmani, BF | 1 |
| Crisp, ED | 1 |
| Kayani, S | 1 |
| Rajab, H | 1 |
| Cilio, MR | 1 |
| Bianchi, R | 1 |
| Balestri, M | 1 |
| Onofri, A | 1 |
| Giovannini, S | 1 |
| Di Capua, M | 1 |
| Vigevano, F | 1 |
| Weber, P | 1 |
| Eue, S | 1 |
| Grumbt, M | 1 |
| Müller, M | 1 |
| Schulze, A | 1 |
| Edelbroek, PM | 1 |
| Tilz, C | 1 |
| Resch, R | 1 |
| Hofer, T | 1 |
| Eggers, C | 1 |
| Gámez-Leyva, G | 1 |
| Aristín, JL | 1 |
| Fernández, E | 1 |
| Pascual, J | 1 |
| Tripathi, M | 2 |
| Vibha, D | 2 |
| Choudhary, N | 1 |
| Prasad, K | 2 |
| Srivastava, MV | 2 |
| Bhatia, R | 2 |
| Chandra, SP | 1 |
| Fattouch, J | 1 |
| Di Bonaventura, C | 1 |
| Casciato, S | 1 |
| Bonini, F | 1 |
| Petrucci, S | 1 |
| Lapenta, L | 1 |
| Manfredi, M | 1 |
| Prencipe, M | 1 |
| Giallonardo, AT | 1 |
| Sugaya, Y | 1 |
| Maru, E | 1 |
| Kudo, K | 1 |
| Shibasaki, T | 1 |
| Kato, N | 1 |
| Fu, Z | 1 |
| Venkatesan, K | 1 |
| Mazzuferi, M | 1 |
| Seutin, V | 1 |
| Vicini, S | 1 |
| Devarajan, J | 1 |
| Siyam, AM | 1 |
| Alexopoulos, AV | 1 |
| Weil, R | 1 |
| Farag, E | 1 |
| Chen, LL | 1 |
| Haneef, Z | 1 |
| Dorsch, A | 1 |
| Keselman, I | 1 |
| Stern, JM | 1 |
| Aiguabella, M | 1 |
| Falip, M | 3 |
| Villanueva, V | 1 |
| de la Peña, P | 1 |
| Molins, A | 1 |
| Garcia-Morales, I | 1 |
| Saiz, RA | 1 |
| Pardo, J | 1 |
| Tortosa, D | 1 |
| Sansa, G | 1 |
| Miró, J | 1 |
| Raj, D | 1 |
| Gulati, S | 1 |
| Lodha, R | 1 |
| Goodwin, H | 2 |
| Hinson, HE | 1 |
| Shermock, KM | 1 |
| Karanjia, N | 1 |
| Lewin, JJ | 1 |
| Alvarez, V | 1 |
| Januel, JM | 1 |
| Burnand, B | 1 |
| Swisher, CB | 1 |
| Doreswamy, M | 1 |
| Gingrich, KJ | 1 |
| Vredenburgh, JJ | 1 |
| Kolls, BJ | 1 |
| Maurya, PK | 1 |
| Leppik, IE | 1 |
| Patterson, EN | 1 |
| Coles, LD | 1 |
| Craft, EM | 1 |
| Cloyd, JC | 1 |
| Ko, SB | 1 |
| Ortega-Gutierrez, S | 1 |
| Choi, HA | 1 |
| Presciutti, M | 1 |
| Schmidt, JM | 1 |
| Badjatia, N | 1 |
| Lee, K | 1 |
| Mayer, SA | 1 |
| Sasidaran, K | 1 |
| Singhi, S | 1 |
| Singhi, P | 1 |
| Liu, X | 1 |
| Wu, Y | 1 |
| Chen, Z | 1 |
| Ma, M | 1 |
| Su, L | 1 |
| Zelano, J | 1 |
| Kumlien, E | 1 |
| Cook, AM | 1 |
| Castle, A | 1 |
| Green, A | 1 |
| Lesch, C | 1 |
| Morrison, C | 1 |
| Rhoney, D | 1 |
| Parker, D | 1 |
| Tesoro, E | 1 |
| Brophy, G | 1 |
| Gokun, J | 1 |
| Makii, J | 1 |
| McAllen, K | 1 |
| Bledsoe, K | 1 |
| Sangha, K | 1 |
| Weant, K | 1 |
| Liang, N | 1 |
| Murphy-Human, T | 1 |
| Vaca, GF | 1 |
| Lenz, T | 1 |
| Knight, EM | 1 |
| Tuxhorn, I | 1 |
| Ju, J | 1 |
| Li, XY | 1 |
| McTague, A | 1 |
| Kneen, R | 1 |
| Kumar, R | 1 |
| Spinty, S | 1 |
| Appleton, R | 1 |
| Kang, SY | 1 |
| Han, YM | 1 |
| Choi, K | 1 |
| Hwang, SH | 1 |
| Tanriverdi, S | 1 |
| Terek, D | 1 |
| Koroglu, OA | 1 |
| Yalaz, M | 1 |
| Tekgul, H | 1 |
| Kultursay, N | 1 |
| Fernández-Torrón, R | 1 |
| Esteve-Belloch, P | 1 |
| Palma, JA | 1 |
| Riverol, M | 1 |
| Iriarte, J | 1 |
| Pohley, I | 1 |
| Rantsch, K | 1 |
| Benecke, R | 1 |
| Isoda, K | 1 |
| Tomoyasu, C | 1 |
| Fujii, N | 1 |
| Nishimura, A | 1 |
| Riviello, JJ | 1 |
| LaRoche, SM | 1 |
| Sperling, MR | 1 |
| Alldredge, B | 1 |
| Bleck, TP | 2 |
| Glauser, T | 1 |
| Shutter, L | 1 |
| Vespa, PM | 1 |
| Bell, R | 1 |
| Brophy, GM | 1 |
| Ermolenko, NA | 1 |
| Ermakov, AIu | 1 |
| Buchneva, IA | 1 |
| Zakharova, EI | 1 |
| Kalikina, TA | 1 |
| Bjørnæs, H | 1 |
| Bakke, KA | 1 |
| Larsson, PG | 1 |
| Heminghyt, E | 1 |
| Rytter, E | 1 |
| Brager-Larsen, LM | 1 |
| Eriksson, AS | 1 |
| Mazarati, AM | 1 |
| Baldwin, R | 1 |
| Wasterlain, CG | 1 |
| Atefy, R | 1 |
| Tettenborn, B | 1 |
| Bromfield, EB | 2 |
| Donaire, A | 2 |
| Carreno, M | 2 |
| Gómez, B | 1 |
| Fossas, P | 1 |
| Bargalló, N | 1 |
| Agudo, R | 1 |
| Setoaín, X | 1 |
| Boget, T | 1 |
| Raspall, T | 1 |
| Obach, V | 1 |
| Rumiá, J | 1 |
| Patel, NC | 1 |
| Landan, IR | 1 |
| Levin, J | 1 |
| Szaflarski, J | 1 |
| Wilner, AN | 1 |
| Kilickap, S | 1 |
| Cakar, M | 1 |
| Onal, IK | 1 |
| Tufan, A | 1 |
| Akoglu, H | 1 |
| Aksoy, S | 1 |
| Erman, M | 1 |
| Tekuzman, G | 1 |
| Gibbs, JE | 2 |
| Walker, MC | 1 |
| Cock, HR | 2 |
| Kröll-Seger, J | 1 |
| Mothersill, IW | 1 |
| Novak, S | 1 |
| Sälke-Kellermann, RA | 1 |
| Krämer, G | 1 |
| Zhou, JL | 1 |
| Zhao, Q | 1 |
| Holmes, GL | 1 |
| Rupprecht, S | 1 |
| Franke, K | 1 |
| Fitzek, S | 1 |
| Witte, OW | 1 |
| Hagemann, G | 1 |
| Amaro, S | 1 |
| Delgado, R | 1 |
| Toledo, M | 1 |
| Maestro, I | 1 |
| Hefft, S | 1 |
| Oehl, B | 1 |
| Brandt, C | 1 |
| Glien, M | 1 |
| Gastens, AM | 1 |
| Fedrowitz, M | 1 |
| Bethmann, K | 1 |
| Volk, HA | 1 |
| Potschka, H | 1 |
| Farooq, MU | 1 |
| Naravetla, B | 1 |
| Majid, A | 1 |
| Gupta, R | 1 |
| Pysh, JJ | 1 |
| Kassab, MY | 1 |
| Trabacca, A | 1 |
| Profice, P | 1 |
| Costanza, MC | 1 |
| Gesualdi, M | 1 |
| De Rinaldis, M | 1 |
| Knake, S | 1 |
| Gruener, J | 1 |
| Hattemer, K | 1 |
| Klein, KM | 1 |
| Bauer, S | 1 |
| Oertel, WH | 1 |
| Hamer, HM | 1 |
| Rosenow, F | 1 |
| Florance, N | 1 |
| Finkel, RS | 1 |
| Alehan, F | 1 |
| Ozcay, F | 1 |
| Haberal, M | 1 |
| Jackson, MJ | 1 |
| Bhushan Singh, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial[NCT04466670] | Phase 2 | 379 participants (Anticipated) | Interventional | 2020-07-11 | Recruiting | ||
| A Multicenter, Randomized, Blinded, Comparative Effectiveness Study of Fosphenytoin, Valproic Acid, or Levetiracetam in the Emergency Department Treatment of Patients With Benzodiazepine-refractory Status Epilepticus.[NCT01960075] | Phase 3 | 478 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Effectiveness of Combined Levetiracetam and Midazolam in Treatment of Generalized Convulsive Status Epilepticus in Children[NCT04926844] | Phase 2 | 144 participants (Actual) | Interventional | 2021-06-20 | Completed | ||
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| Efficiency of Levetiracetam Intravenous in Association With Clonazepam Versus Clonazepam Alone in Prehospital Care of Generalised Tonicoclonic Status Epilepticus[NCT01150331] | Phase 3 | 203 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Intravenous Levetiracetam as First-line Anticonvulsive Treatment in Patients With Non-convulsive Status Epilepticus[NCT00603135] | Phase 2 | 0 participants (Actual) | Interventional | 2008-01-31 | Withdrawn | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Length of hospital stay in days (NCT01960075)
Timeframe: length of hospital stay
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 3 |
| Levetiracetam | 3 |
Length of stay is determined by the number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study. (NCT01960075)
Timeframe: number of calendar days after the day of ED arrival until hospital discharge or subject end-of-study
| Intervention | days (Median) |
|---|---|
| Fosphenytoin (FOS) | 1 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
The time to termination of seizures is the interval from the start of study drug infusion to cessation of clinically apparent seizure in those who meet the primary outcome. (NCT01960075)
Timeframe: start of drug infusion to seizure cessation
| Intervention | minutes (Median) |
|---|---|
| Fosphenytoin (FOS) | 11.7 |
| Valproic Acid | 7.0 |
| Levetiracetam | 10.5 |
ICU admission is recorded as occurring only if the ICU is the initial inpatient unit for the patient. (NCT01960075)
Timeframe: Admission to intensive care unit after start of study drug infusion, where the ICU is the initial inpatient unit for the patient
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 70 |
| Valproic Acid | 71 |
| Levetiracetam | 87 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. The Adjudicated outcomes analysis is different from Outcome measure 1 because a central clinical phenomenology core of four neurologists adjudicated from the medical records the time to seizure cessation, the time in status epilepticus before trial-drug initiation, and the cause of the seizure. For each enrollment, two neurologists from this core group conducted independent initial reviews and then determined a consensus or consulted a third adjudicator, as needed. Adjudicators were unaware of the treatment assignments and made determinations by medical record review. (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 57 |
| Valproic Acid | 60 |
| Levetiracetam | 67 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Intention to treat (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 53 |
| Valproic Acid | 56 |
| Levetiracetam | 68 |
Determined by the absence of clinically apparent seizures and improving consciousness at 1 hour without other anticonvulsant medications. Per-protocol analysis (NCT01960075)
Timeframe: Within 60 minutes after the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 37 |
| Valproic Acid | 43 |
| Levetiracetam | 51 |
Acute anaphylaxis is defined as a clinical presentation consistent with life threatening allergic reaction occurring within 6 hours of the start of study drug infusions and manifested as urticaria in combination with either (1) a systolic blood pressure of < 90 mmHg sustained for greater than 5 minutes, or (2) objective evidence of airway obstruction, and for which the patient was treated with antihistamines and/or steroids. (NCT01960075)
Timeframe: within 6 hours of the start of study drug infusions
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Respiratory depression is defined as impairment of ventilation or oxygenation necessitating definitive endotracheal intubation and mechanical ventilation. It is distinct from intubations performed only for airway protection in those with decreased levels of consciousness. It does not include those getting only supraglottic airways or transient bag-valve-mask support. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 16 |
| Valproic Acid | 10 |
| Levetiracetam | 12 |
acute seizure recurrence 60 minutes to 12 hours after start of study drug infusion (NCT01960075)
Timeframe: 60 minutes to 12 hours after start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 14 |
| Valproic Acid | 14 |
| Levetiracetam | 16 |
Safety outcome: Death (NCT01960075)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 3 |
| Valproic Acid | 2 |
| Levetiracetam | 7 |
Endotracheal intubation within 60 minutes of start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 33 |
| Valproic Acid | 21 |
| Levetiracetam | 30 |
Safety outcome: Hepatic transaminase or ammonia elevations (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 1 |
| Levetiracetam | 1 |
Life-threatening hypotension within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 4 |
| Valproic Acid | 2 |
| Levetiracetam | 1 |
Life-threatening cardiac arrhythmia within 60 minutes of the start of study drug infusion (NCT01960075)
Timeframe: within 60 minutes of the start of study drug infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 1 |
Purple glove syndrome is defined as the presence of all three of the findings of the objective edema: discoloration, and pain in the distal extremity in which study drug was administered, with or without known extravasation, and for which there is no other evident etiology. (NCT01960075)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 0 |
| Valproic Acid | 0 |
| Levetiracetam | 0 |
Number of participants with seizure cessation within 20 minutes of study drug initiation for patients with treatment success. This outcome measure was only reported in the Supplementary materials to the Primary Paper. (NCT01960075)
Timeframe: within 20 minutes
| Intervention | Participants (Count of Participants) |
|---|---|
| Fosphenytoin (FOS) | 43 |
| Valproic Acid | 43 |
| Levetiracetam | 53 |
17 reviews available for piracetam and Absence Status
| Article | Year |
|---|---|
Clinical considerations for rapid administration of undiluted or minimally diluted levetiracetam bolus doses.
Topics: Administration, Intravenous; Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Human | 2022 |
Levetiracetam vs. phenytoin as 2nd-line treatment for status epilepticus: A systematic review and meta-analysis.
Topics: Anticonvulsants; Benzodiazepines; Drug Therapy, Combination; Humans; Levetiracetam; Phenytoin; Pirac | 2020 |
Pediatric status epilepticus: improved management with new drug therapies?
Topics: Algorithms; Anticonvulsants; Child; Clinical Protocols; Humans; Ketamine; Levetiracetam; Midazolam; | 2017 |
Why we prefer levetiracetam over phenytoin for treatment of status epilepticus.
Topics: Administration, Cutaneous; Administration, Intravenous; Anticonvulsants; Exanthema; Humans; Infusion | 2018 |
Levetiracetam for the treatment of status epilepticus.
Topics: Anticonvulsants; Humans; Levetiracetam; Nootropic Agents; Piracetam; Status Epilepticus | 2015 |
Pharmacologic treatment of status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Humans; Ketamine; Levetiracetam; Piracetam; Randomized Controlled | 2016 |
Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus.
Topics: Anticonvulsants; Humans; Levetiracetam; Phenytoin; Piracetam; Status Epilepticus; Valproic Acid | 2016 |
Review and update of the Hong Kong Epilepsy Guideline on status epilepticus.
Topics: Acetamides; Anticonvulsants; Diet, Ketogenic; Hong Kong; Humans; Lacosamide; Levetiracetam; Magnesiu | 2017 |
[Drugs for status epilepticus treatment].
Topics: Anticonvulsants; Barbiturates; Benzodiazepines; Fructose; Humans; Hypnotics and Sedatives; Levetirac | 2009 |
What is the relative value of the standard anticonvulsants: Phenytoin and fosphenytoin, phenobarbital, valproate, and levetiracetam?
Topics: Anticonvulsants; Benzodiazepines; Humans; Levetiracetam; Phenobarbital; Phenytoin; Piracetam; Prodru | 2009 |
What is the evidence to use new intravenous AEDs in status epilepticus?
Topics: Acetamides; Humans; Injections, Intraventricular; Lacosamide; Levetiracetam; Lipoproteins; Piracetam | 2011 |
Management of acute seizure and status epilepticus in pediatric emergency.
Topics: Anesthesia, Intravenous; Anticonvulsants; Benzodiazepines; Child; Child, Preschool; Combined Modalit | 2012 |
A systematic review of randomized controlled trials on the theraputic effect of intravenous sodium valproate in status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Injections, Intravenous; Levetiracetam; Phenytoin; Piracetam; Ran | 2012 |
Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review.
Topics: Anticonvulsants; Humans; Levetiracetam; Piracetam; Status Epilepticus | 2012 |
[Experience with levetiracetam in the treatment of status epilepticus].
Topics: Anticonvulsants; Epilepsia Partialis Continua; Humans; Levetiracetam; Piracetam; Status Epilepticus | 2013 |
The use of valproate and new antiepileptic drugs in status epilepticus.
Topics: Anticonvulsants; Drug Approval; Fructose; Humans; Infusions, Intravenous; Injections, Intravenous; L | 2007 |
Intensive care unit management of patients with status epilepticus.
Topics: Anesthesia, General; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administration Schedule | 2007 |
18 trials available for piracetam and Absence Status
| Article | Year |
|---|---|
Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: A prospective, randomized study.
Topics: Adult; Anticonvulsants; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; Phenytoin; Pira | 2017 |
Emergency treatment with levetiracetam or phenytoin in status epilepticus in children-the EcLiPSE study: study protocol for a randomised controlled trial.
Topics: Adolescent; Age Factors; Anticonvulsants; Child; Child, Preschool; Clinical Protocols; Emergencies; | 2017 |
A multicentre randomised controlled trial of levetiracetam versus phenytoin for convulsive status epilepticus in children (protocol): Convulsive Status Epilepticus Paediatric Trial (ConSEPT) - a PREDICT study.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clinical Protocols; Emergencies; Emergency Ser | 2017 |
Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus.
Topics: Administration, Rectal; Animals; Anticonvulsants; Dog Diseases; Dogs; Female; Levetiracetam; Male; P | 2018 |
Bayesian adaptive trials offer advantages in comparative effectiveness trials: an example in status epilepticus.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Bayes Theorem; Child; Child, Preschool; Comparative Effect | 2013 |
The established status epilepticus trial 2013.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Child, Preschool; Double-Blind M | 2013 |
Efficacy of levetiracetam in electrical status epilepticus during sleep of children: a multicenter experience.
Topics: Anticonvulsants; Brain; Child; Child, Preschool; Electroencephalography; Female; Follow-Up Studies; | 2014 |
Levetiracetam versus phenytoin in management of status epilepticus.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Anticonvulsants; Disease Management; Female; H | 2015 |
Management of generalised convulsive status epilepticus (SE): A prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam--Pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Drug Therapy, Combination; Electroencephalography; Epileps | 2015 |
A comparison of four antiepileptic drugs in status epilepticus: experience from India.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; India; Infant; Le | 2016 |
Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Anticonvulsants; Clonazepam; Double-Blind Method; Drug Therapy, Combination; Emergency | 2016 |
Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.
Topics: Adult; Aged; Anticonvulsants; Bayes Theorem; Biological Availability; Dose-Response Relationship, Dr | 2009 |
Management of refractory status epilepticus at a tertiary care centre in a developing country.
Topics: Adolescent; Adult; Anticonvulsants; Developing Countries; Electroencephalography; Female; Humans; In | 2010 |
Intravenous Levetiracetam as first-line treatment of status epilepticus in the elderly.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Female; Geriatrics; Humans; Injections, Intravenous; Levet | 2010 |
Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study.
Topics: Adolescent; Adult; Aged; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Levetirac | 2012 |
Canine status epilepticus: a translational platform for human therapeutic trials.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Double-Bli | 2011 |
A prehospital randomized trial in convulsive status epilepticus.
Topics: Adult; Anticonvulsants; Clonazepam; Double-Blind Method; Drug Therapy, Combination; Emergency Medica | 2011 |
Subclinical epileptiform activity in children with electrical status epilepticus during sleep: effects on cognition and behavior before and after treatment with levetiracetam.
Topics: Action Potentials; Anticonvulsants; Child; Child Behavior; Child, Preschool; Cognition Disorders; Do | 2013 |
100 other studies available for piracetam and Absence Status
| Article | Year |
|---|---|
Efficacy of intravenous levetiracetam versus phenytoin in convulsive status epilepticus and acute repetitive seizures in children.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infusions, Intravenous | 2022 |
Regulation of Inflammation-Related Genes through
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Inflammation; Levetiracetam; Mice; Piloc | 2022 |
An aqueous extract of Syzygium cumini protects against kainate-induced status epilepticus and amnesia: evidence for antioxidant and anti-inflammatory intervention.
Topics: Amnesia; Animals; Anti-Inflammatory Agents; Anticonvulsants; Antioxidants; Kainic Acid; Mice; Pirace | 2022 |
Status epilepticus prognosis following levetiracetam administration: Analysis of loading doses.
Topics: Adult; Anticonvulsants; Humans; Levetiracetam; Piracetam; Prognosis; Prospective Studies; Retrospect | 2023 |
Blood concentration of levetiracetam after bolus administration in patients with status epilepticus.
Topics: Anticonvulsants; Diazepam; Humans; Levetiracetam; Piracetam; Seizures; Status Epilepticus | 2021 |
Rapid administration of undiluted intravenous levetiracetam.
Topics: Adult; Anticonvulsants; Drug-Related Side Effects and Adverse Reactions; Epilepsy; Humans; Levetirac | 2021 |
The efficacy of different kinds of intravenously applied antiepileptic drugs in the treatment of status epilepticus. How can it be determined?
Topics: Acetamides; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; He | 2017 |
Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures after status epilepticus.
Topics: Administration, Intravenous; Administration, Oral; Anticonvulsants; Blood Pressure; Databases, Factu | 2017 |
Treatment outcomes after the introduction of a new seizure management protocol.
Topics: Adult; Anticonvulsants; Clinical Protocols; Drug-Related Side Effects and Adverse Reactions; Emergen | 2018 |
The effect of levetiracetam on status epilepticus-induced neuronal death in the rat hippocampus.
Topics: Animals; Behavior, Animal; Cell Death; Diazepam; Disease Models, Animal; Drug Therapy, Combination; | 2013 |
A case of nonconvulsive status epilepticus with a reversible contralateral cerebellar lesion: temporal changes in magnetic resonance imaging and single-photon emission computed tomography finding.
Topics: Aged; Anticonvulsants; Brain Waves; Cerebellum; Cerebrovascular Circulation; Diffusion Magnetic Reso | 2013 |
Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus.
Topics: Acetamides; Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants | 2014 |
Considerations in prophylaxis for tumor-associated epilepsy: prevention of status epilepticus and tolerability of newer generation AEDs.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Brain Neoplasms; Female; Humans; Levetiracetam; Male; Midd | 2013 |
The safety and tolerability of different intravenous administrations of levetiracetam, bolus versus infusion, in intensive care unit patients.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Infusi | 2014 |
Effectiveness of intravenous levetiracetam as an adjunctive treatment in pediatric refractory status epilepticus.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Levet | 2014 |
[Efficacy of levetiracetam combined with short-term clonazepam in treatment of electrical status epilepticus during sleep in children with benign childhood epilepsy with centrotemporal spikes].
Topics: Anticonvulsants; Child; Child, Preschool; Clonazepam; Drug Therapy, Combination; Electroencephalogra | 2014 |
Effect of levetiracetam in acute encephalitis with refractory, repetitive partial seizures during acute and chronic phase.
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Bromides; Child; Chronic Disease; Encephalitis; F | 2015 |
Pretreatment with intravenous levetiracetam in the rhesus monkey Coriaria lactone-induced status epilepticus model.
Topics: Administration, Intravenous; Animals; Anticonvulsants; Disease Models, Animal; Humans; Lactones; Lev | 2015 |
Levetiracetam efficacy in children with epilepsy with electrical status epilepticus in sleep.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; China; Epilepsy; Female; Humans; Infant; Levet | 2015 |
Prevention of status epilepticus-induced brain edema and neuronal cell loss by repeated treatment with high-dose levetiracetam.
Topics: Animals; Anticonvulsants; Brain Edema; Cell Death; Disease Models, Animal; Levetiracetam; Magnetic R | 2015 |
[Dramatic seizure reduction with levetiracetam in adult Dravet syndrome: a case report].
Topics: Adult; Drug Therapy, Combination; Epilepsies, Myoclonic; Humans; Levetiracetam; Male; Piracetam; Sta | 2015 |
Intravenous levetiracetam in Thai children and adolescents with status epilepticus and acute repetitive seizures.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Humans; Infant; Infant, Newborn; Infus | 2015 |
Intravenous levetiracetam in clinical practice--Results from an independent registry.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Child; Chi | 2015 |
Intravenous levetiracetam treatment in status epilepticus: A prospective study.
Topics: Administration, Intravenous; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Diazepam; | 2015 |
Status epilepticus induction has prolonged effects on the efficacy of antiepileptic drugs in the 6-Hz seizure model.
Topics: Animals; Anticonvulsants; Carbamazepine; Diazepam; Disease Models, Animal; Levetiracetam; Male; Mice | 2015 |
Early pregnancy cerebral venous thrombosis and status epilepticus treated with levetiracetam and lacosamide throughout pregnancy.
Topics: Acetamides; Adult; Anticonvulsants; Female; Fetal Blood; Humans; Infant, Newborn; Lacosamide; Leveti | 2015 |
A rare cause of status epilepticus; alpha lipoic acid intoxication, case report and review of the literature.
Topics: Anticonvulsants; Epilepsies, Myoclonic; Female; Humans; Infant; Levetiracetam; Midazolam; Piracetam; | 2015 |
[FOCAL MOTOR SEIZURES AND STATUS EPILEPTICUS PROVOKED BY MIRTAZAPINE].
Topics: Adult; Anticonvulsants; Antidepressive Agents, Tricyclic; Carbamazepine; Electroencephalography; Epi | 2015 |
[Cases of non-standard approach to treatment of super-refractory status epilepticus].
Topics: Adult; Anesthetics, Intravenous; Anticonvulsants; Clinical Protocols; Drug Therapy, Combination; Ele | 2015 |
Dr No: double drug fails to eliminate status epilepticus.
Topics: Clonazepam; Emergency Medical Services; Female; Humans; Male; Piracetam; Status Epilepticus | 2016 |
Case report: absence-status as late reexacerbation of genetic epilepsy of adolescence.
Topics: Adolescent; Age of Onset; Anticonvulsants; Electroencephalography; Epilepsy, Absence; Humans; Leveti | 2016 |
Seizure and Fever.
Topics: Acyclovir; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antiviral Agents; Brain Neoplasms; Ceftri | 2016 |
Evaluation of the pentylenetetrazole seizure threshold test in epileptic mice as surrogate model for drug testing against pharmacoresistant seizures.
Topics: Animals; Anticonvulsants; Diazepam; Disease Models, Animal; Drug Resistance; Epilepsy; GABA Antagoni | 2016 |
A Comparison of Intravenous Levetiracetam and Valproate for the Treatment of Refractory Status Epilepticus in Children.
Topics: Administration, Intravenous; Adolescent; Anticonvulsants; Child; Child, Preschool; Clinical Protocol | 2016 |
Teaching NeuroImages: De novo absence status epilepticus in an adult.
Topics: Anticonvulsants; Benzodiazepines; Brain; Electroencephalography; Humans; Levetiracetam; Male; Middle | 2016 |
Levetiracetam treatment influences blood-brain barrier failure associated with angiogenesis and inflammatory responses in the acute phase of epileptogenesis in post-status epilepticus mice.
Topics: Acute Disease; Animals; Anticonvulsants; Astrocytes; Blood-Brain Barrier; Brain Edema; Capillary Per | 2016 |
Levetiracetam-induced thrombocytopenia in a patient with status epilepticus.
Topics: Aged; Anticonvulsants; Female; Humans; Levetiracetam; Piracetam; Status Epilepticus; Thrombocytopeni | 2017 |
Termination of absence status epilepticus by low-dose intravenous levetiracetam.
Topics: Adult; Anticonvulsants; Drug Administration Schedule; Electroencephalography; Humans; Injections, In | 2008 |
Levetiracetam (keppra) in the treatment of refractory status epilepticus.
Topics: Adult; Anticonvulsants; Electroencephalography; Humans; Levetiracetam; Male; Piracetam; Refractory P | 2007 |
Decreased expression of synaptic vesicle protein 2A, the binding site for levetiracetam, during epileptogenesis and chronic epilepsy.
Topics: Adolescent; Adult; Animals; Anticonvulsants; Blotting, Western; Child; Disease Models, Animal; Epile | 2009 |
Effects of chronic treatment with levetiracetam on hippocampal field responses after pilocarpine-induced status epilepticus in rats.
Topics: Animals; Anticonvulsants; Dose-Response Relationship, Drug; Hippocampus; Humans; Levetiracetam; Male | 2008 |
Levetiracetam in children with refractory status epilepticus.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Drug Resistance; Electroencephalography; Femal | 2009 |
Intravenous levetiracetam for epileptic seizure emergencies in older people.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Drug Tolerance; Emergencies; Epilepsy; Epilepsy, Complex P | 2009 |
Levetiractam in the treatment of two children with myoclonic status epilepticus.
Topics: Anticonvulsants; Child; Electroencephalography; Humans; Infant; Levetiracetam; Male; Piracetam; Stat | 2009 |
The role of the newer antiepileptic drugs in the treatment of generalized convulsive status epilepticus.
Topics: Anticonvulsants; Humans; Levetiracetam; Piracetam; Status Epilepticus; Valproic Acid | 2008 |
Symptomatic complex partial status epilepticus manifesting as utilization behavior of a mobile phone.
Topics: Anticonvulsants; Benzodiazepines; Brain Neoplasms; Cell Phone; Clobazam; Electroencephalography; Epi | 2009 |
Intravenous levetiracetam in critically ill children with status epilepticus or acute repetitive seizures.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child; Child, Preschool; Cohort Studies; Critical Illnes | 2009 |
Levetiracetam-induced pancytopenia.
Topics: Aged; Anticonvulsants; Female; Humans; Levetiracetam; Pancytopenia; Piracetam; Status Epilepticus | 2009 |
Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome.
Topics: Anticonvulsants; Child; Drug Therapy, Combination; Electroencephalography; Epilepsies, Partial; Fema | 2009 |
Intravenous levetiracetam: a new treatment alternative for refractory status epilepticus.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Drug Administrati | 2009 |
Intravenous levetiracetam as treatment for status epilepticus.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Injections, Intravenous; Levetirace | 2009 |
Role of intravenous levetiracetam in acute seizure management of children.
Topics: Adolescent; Anticonvulsants; Brain; Chemotherapy, Adjuvant; Child; Child, Preschool; Electroencephal | 2009 |
Intravenous levetiracetam terminates refractory status epilepticus in two patients with migrating partial seizures in infancy.
Topics: Ammonia; Anticonvulsants; Blood Cell Count; Creatine; Drug Administration Schedule; Electroencephalo | 2009 |
Levetiracetam in nonconvulsive status epilepticus in a child with Angelman syndrome.
Topics: Angelman Syndrome; Anticonvulsants; Brain; Child; Electroencephalography; Humans; Levetiracetam; Mal | 2010 |
Two years of experience in the treatment of status epilepticus with intravenous levetiracetam.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Cerebrovascular Disorders; Epilepsies, | 2009 |
Improved seizure control by alternating therapy of levetiracetam and valproate in epileptic rats.
Topics: Animals; Anticonvulsants; Dentate Gyrus; Disease Models, Animal; Drug Administration Schedule; Drug | 2010 |
Successful treatment for refractory convulsive status epilepticus by non-parenteral lacosamide.
Topics: Acetamides; Adult; Anticonvulsants; Diazepam; Drug Resistance; Drug Therapy, Combination; Epilepsy; | 2010 |
Experience with intravenous levetiracetam in status epilepticus: a retrospective case series.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Child; Dose-Response Relat | 2009 |
Levetiracetam suppresses development of spontaneous EEG seizures and aberrant neurogenesis following kainate-induced status epilepticus.
Topics: Animals; Animals, Newborn; Bromodeoxyuridine; Dentate Gyrus; Disease Models, Animal; Electroencephal | 2010 |
11-Deoxycortisol impedes GABAergic neurotransmission and induces drug-resistant status epilepticus in mice.
Topics: Animals; Anticonvulsants; Cerebellum; Cortodoxone; Dose-Response Relationship, Drug; Drug Resistance | 2011 |
Non-convulsive status epilepticus in the postanesthesia care unit following meningioma excision.
Topics: Aged, 80 and over; Anticonvulsants; Craniotomy; Electroencephalography; Female; Humans; Levetiraceta | 2011 |
Successful treatment of refractory simple motor status epilepticus with lacosamide and levetiracetam.
Topics: Acetamides; Anticonvulsants; Humans; Lacosamide; Levetiracetam; Magnetic Resonance Imaging; Male; Mi | 2011 |
Efficacy of intravenous levetiracetam as an add-on treatment in status epilepticus: a multicentric observational study.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Injections, Intravenous; Levetirace | 2011 |
Status epilepticus.
Topics: Anticonvulsants; Benzodiazepines; Child; Clinical Protocols; Fructose; GABA Modulators; Humans; Keta | 2011 |
The use of lacosamide in refractory status epilepticus.
Topics: Acetamides; Aged; Aged, 80 and over; Angioedema; Anticonvulsants; Drug Administration Schedule; Drug | 2011 |
Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam.
Topics: Aged; Analysis of Variance; Anticonvulsants; Chi-Square Distribution; Female; Humans; Levetiracetam; | 2011 |
Phenytoin, levetiracetam, and pregabalin in the acute management of refractory status epilepticus in patients with brain tumors.
Topics: Acute Disease; Aged; Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Female; gamma-Amin | 2012 |
Status epilepticus-induced hyperemia and brain tissue hypoxia after cardiac arrest.
Topics: Aged, 80 and over; Body Temperature; Brain; Cerebrovascular Circulation; Electroencephalography; Hum | 2011 |
Practice variations in the management of status epilepticus.
Topics: Adult; Aged; Anticonvulsants; Benzodiazepines; Critical Care; Female; Humans; Levetiracetam; Male; M | 2012 |
Gaucher disease: successful treatment of myoclonic status epilepticus with levetiracetam.
Topics: Adolescent; Anticonvulsants; Electroencephalography; Epilepsies, Myoclonic; Gaucher Disease; Humans; | 2012 |
[Therapeutic effects of levetiracetam on electrical status epilepticus during sleep in children].
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Electroencephalography; Female; Humans; Infant | 2012 |
Intravenous levetiracetam in acute repetitive seizures and status epilepticus in children: experience from a children's hospital.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Female; Hospitals, Pediatric; Humans; Infant; | 2012 |
Neurological picture. Transient high-intensity signal of heterotopia on DWI in an epilepsy patient.
Topics: Anticonvulsants; Brain; Carbamazepine; Choristoma; Consciousness Disorders; Diagnosis, Differential; | 2012 |
Neonatal status epilepticus controlled with levetiracetam at Sturge Weber syndrome.
Topics: Anticonvulsants; Electroencephalography; Female; Humans; Infant, Newborn; Levetiracetam; Magnetic Re | 2013 |
[Prolonged hemiplegia as the only symptom of a simple focal nonconvulsive status epilepticus].
Topics: Anticonvulsants; Bacteriuria; Diagnosis, Differential; Diffusion Magnetic Resonance Imaging; Electro | 2012 |
[Levetiracetam-induced aggravation to non-convulsive status epilepticus in a boy with Lennox-Gastaut syndrome].
Topics: Anticonvulsants; Child; Humans; Intellectual Disability; Lennox Gastaut Syndrome; Levetiracetam; Mal | 2012 |
Treatment of status epilepticus: an international survey of experts.
Topics: Administration, Intravenous; Adult; Anticonvulsants; Child; Consensus; Expert Testimony; Humans; Hyp | 2013 |
[Epilepsies with electric status epilepticus in sleep: peculiarities of clinical course and rational approaches to treatment].
Topics: Adolescent; Anticonvulsants; Carbamazepine; Child; Child, Preschool; Drug Resistance; Electricity; E | 2011 |
Anticonvulsant effects of levetiracetam and levetiracetam-diazepam combinations in experimental status epilepticus.
Topics: Action Potentials; Animals; Anticonvulsants; Diazepam; Dose-Response Relationship, Drug; Drug Therap | 2004 |
Nonconvulsive status epilepticus on treatment with levetiracetam.
Topics: Adult; Aged; Anticonvulsants; Electroencephalography; Humans; Levetiracetam; Male; Piracetam; Status | 2005 |
Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Levetiracetam; Male; Middle Aged; P | 2005 |
Cortical laminar necrosis related to prolonged focal status epilepticus.
Topics: Adult; Anticonvulsants; Aphasia, Wernicke; Brain Diseases; Cerebral Cortex; Functional Laterality; H | 2006 |
The use of levetiracetam in refractory status epilepticus.
Topics: Adolescent; Adult; Aged, 80 and over; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therap | 2006 |
Nonconvulsive status epilepticus due to ifosfamide.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Female; Humans; Ifosfamide; Levetirace | 2006 |
Determinants of success in the use of oral levetiracetam in status epilepticus.
Topics: Administration, Oral; Anticonvulsants; Dose-Response Relationship, Drug; Female; Humans; Intubation, | 2006 |
Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus.
Topics: Aconitate Hydratase; Animals; Anticonvulsants; Chromatography, High Pressure Liquid; Citrate (si)-Sy | 2006 |
Levetiracetam-induced myoclonic status epilepticus in myoclonic-astatic epilepsy: a case report.
Topics: Anticonvulsants; Behavior; Child, Preschool; Electroencephalography; Electromyography; Epilepsies, M | 2006 |
Effect of levetiracetam on visual-spatial memory following status epilepticus.
Topics: Animals; Anticonvulsants; Behavior, Animal; Cell Death; Disease Models, Animal; Electroencephalograp | 2007 |
Administration of levetiracetam after prolonged status epilepticus does not protect from mitochondrial dysfunction in a rodent model.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Electric Stimulation; Electroencephalography; Leve | 2007 |
Levetiracetam as a treatment option in non-convulsive status epilepticus.
Topics: Aged; Aged, 80 and over; Anticonvulsants; Electroencephalography; Epilepsies, Partial; Female; Follo | 2007 |
Use of levetiracetam in hospitalized patients.
Topics: Adult; Aged; Anticonvulsants; Comorbidity; Drug Administration Schedule; Drug Therapy, Combination; | 2006 |
Termination of complex partial status epilepticus by intravenous levetiracetam.
Topics: Adult; Anticonvulsants; Electroencephalography; Female; Humans; Infusions, Intravenous; Levetiraceta | 2009 |
Prophylactic treatment with levetiracetam after status epilepticus: lack of effect on epileptogenesis, neuronal damage, and behavioral alterations in rats.
Topics: Amygdala; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Brain Damage, Chronic; D | 2007 |
IV levetiracetam in the management of non-convulsive status epilepticus.
Topics: Aged, 80 and over; Anticonvulsants; Electroencephalography; Humans; Infusions, Intravenous; Levetira | 2007 |
Levetiracetam in nonconvulsive status epilepticus in childhood: a case report.
Topics: Anticonvulsants; Child; Electroencephalography; Humans; Levetiracetam; Male; Piracetam; Status Epile | 2007 |
Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticonvulsants; Benzodiazepines; Dose-Respons | 2008 |
Intravenous levetiracetam terminates refractory focal status epilepticus.
Topics: Anticonvulsants; Humans; Infusions, Intravenous; Levetiracetam; Male; Piracetam; Status Epilepticus; | 2009 |
The use of levetiracetam in a child with nonconvulsive status epilepticus.
Topics: Anticonvulsants; Child; Female; Humans; Immunosuppressive Agents; Levetiracetam; Liver Transplantati | 2008 |
Should we accept the status quo? Time for new trials in status epilepticus.
Topics: Adult; Anticonvulsants; Electroencephalography; Epilepsy, Complex Partial; Humans; Infusions, Intrav | 2008 |
Use of propofol anesthesia and adjunctive treatment with levetiracetam and gabapentin in managing status epilepticus in a patient of acute intermittent porphyria.
Topics: Amines; Anesthetics, Intravenous; Anticonvulsants; Child; Comorbidity; Cyclohexanecarboxylic Acids; | 2008 |